Clinical Report: AstraZeneca, Daiichi turn to precision medicine after OS miss for Dato-DXd

Datopotamab failed to significantly increase overall survival as second-line therapy for non-small cell lung cancer in a Phase III study. However, a new biomarker and encouraging data in a subset of patients gives the partners another play in the indication and shows, again, the power of precision medicine. 

In the TROPION-Lung01 study, Datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate (ADC) from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568), led to 12.9 months of overall survival, compared with 11.8 months in the docetaxel control arm. The study population included patients with actionable mutations, including EGFR and ALK. ...